Mount Sinai researchers receive $4M in grant awards for junior scientists

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Two Mount Sinai cancer researchers will be awarded $4 million in total costs from the National Institutes of Health Common Fund, which supports high-impact programs and research by junior scientists around the country.

Deborah Marshall, assistant professor of radiation oncology at The Tisch Cancer Institute and The Blavatnik Family Women’s Health Research Institute at the Icahn School of Medicine at Mount Sinai, and Jalal Ahmed Khan, assistant professor of radiation oncology at the Precision Immunology Institute and The Tisch Cancer Institute, each received an Early Independence Award worth $2 million given out over five years. 

This award, established in 2011, provides an opportunity for junior scientists to skip traditional postdoctoral training and move immediately into independent research positions.

Marshall’s study seeks to define novel predictors of female sexual dysfunction and to identify quantitative imaging and microbiome-based biomarker indices associated with damage to specific sexual organs from radiation oncology treatments. Results of the study will rapidly provide transformative data and inform personalized interventions to preserve female sexual function or mitigate the effects of radiation in this understudied population.

Ahmed Khan’s study seeks to advance the cancer therapy known as chimeric antigen receptor CAR T-cell therapy for solid tumors by manipulating CAR T cell interactions with the immune tumor microenvironment. 

The lab will use tumor models to understand the parameters driving the activity and fate of CAR T cells, and design novel CAR T-cell therapies that capitalize on the immunobiology of solid tumors to form durable anti-tumor responses.

In addition to providing advanced radiotherapy to a diverse population of cancer patients, Marshall directs a laboratory aiming to advance the understanding of the impacts of radiotherapy on sexual function in women and female-bodied cancer patients across the lifespan. The lab applies radiobiological imaging, and multi-omic methods in human research to prevent and mitigate the effects of radiotherapy on sexual function and improve quality of life after cancer treatment.

Ahmed Khan leads the Ahmed Khan lab, which is part of the interdisciplinary Precision Immunology Institute and The Tisch Cancer Institute at Icahn Mount Sinai. The lab is recruiting student and postdoctoral researchers in immunology and immunotherapy.

This work is supported by the NIH Common Fund under award numbers DP5OD031876 and DP5OD031828 to Marshall and Ahmed Khan, respectively.

Table of Contents

YOU MAY BE INTERESTED IN

At the Sept. 4 meeting of the National Cancer Advisory Board, NCI Principal Deputy Director Douglas R. Lowy provided an overview of how NCI is weathering the maelstrom of executive orders, policy changes, and funding uncertainties that has come down on federal agencies and research institutes since Donald Trump’s inauguration in January. 
A Senate hearing that the administration hoped would be a routine check-in on the president’s 2026 MAHA-driven healthcare agenda erupted into a political firestorm as senators jumped at their first opportunity to confront HHS Secretary Robert F. Kennedy Jr. over the chaos engulfing the Centers for Disease Control and Prevention.
In December 1971, President Richard Nixon signed the National Cancer Act and declared a “War on Cancer.” In the past 54 years, the U.S. has invested $180 billion nominally, or approximately $322 billion when adjusted for inflation, in cancer research. This investment has paid dividends with more than 100 anticancer drugs brought to market in half a century—virtually all traceable to National Cancer Institute funding. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login